Bain Capital

Lincoln Financial Group is a Fortune 500 insurance and financial services company based in Radnor, Pennsylvania, established in 1905 with the endorsement of Robert Todd Lincoln, the son of Abraham Lincoln. The company is dedicated to providing a wide range of products, including life insurance, annuities, retirement plan services, and group protection. It focuses on wealth protection, accumulation, and retirement income solutions, aiming to help individuals secure better futures for themselves and their families. With over a century of experience, Lincoln Financial Group has built its reputation on the principles and ideals associated with Abraham Lincoln, emphasizing honesty and dependability in its financial services.

HealthEdge is a technology company that provides an integrated software platform designed for healthcare payors. Founded in December 2004 by Albert Waxman and Rob Gillette, HealthEdge specializes in delivering innovative solutions that help health insurers enhance operational efficiency, improve patient outcomes, and significantly lower administrative costs. The company's flagship product suite, HealthRules, is built on patented technology and can be deployed via the HealthEdge Cloud or on-premises. This platform encompasses various functionalities, including claims and benefits administration, care management, and business intelligence, enabling clients to adopt new business models and streamline processes within the healthcare delivery system. In 2012, HealthEdge expanded its offerings by acquiring Click4Care, which enhanced its capabilities in clinical care management. Headquartered in Burlington, Massachusetts, HealthEdge also has a research and development center in Powell, Ohio.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Cofactr, founded in 2021 by Matthew Haber and Phillip Gulley in New York, specializes in supply chain automation and procurement optimization for critical industries such as aerospace, defense, medtech, and robotics. The company offers an automated electronics purchasing assistant that aids hardware teams in sourcing necessary components by connecting them with global suppliers. Cofactr's platform features powerful supply chain intelligence, intuitive forecasting, transparent search capabilities, automated quoting, and instant purchasing. By streamlining these processes, Cofactr enables clients to proactively address sourcing challenges and reduce supply issues, ensuring the timely delivery of essential hardware.

CereVasc, Inc. is a medical device company dedicated to developing innovative, minimally invasive treatments for neurological diseases. Founded in 2014 and based in Auburndale, Massachusetts, the company focuses on its flagship product, the eShunt System. This system provides an endovascularly deliverable cerebrospinal fluid shunt along with necessary delivery components, designed to eliminate the need for invasive surgical procedures, general anesthesia, and prolonged hospitalization associated with traditional treatments for communicating hydrocephalus. By offering a less invasive option, the eShunt System aims to enhance patient outcomes and reduce the overall costs of surgical interventions for this serious condition.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Cofactr, founded in 2021 by Matthew Haber and Phillip Gulley in New York, specializes in supply chain automation and procurement optimization for critical industries such as aerospace, defense, medtech, and robotics. The company offers an automated electronics purchasing assistant that aids hardware teams in sourcing necessary components by connecting them with global suppliers. Cofactr's platform features powerful supply chain intelligence, intuitive forecasting, transparent search capabilities, automated quoting, and instant purchasing. By streamlining these processes, Cofactr enables clients to proactively address sourcing challenges and reduce supply issues, ensuring the timely delivery of essential hardware.

Alkeus Pharmaceuticals is a Boston-based clinical-stage biopharmaceutical company dedicated to developing treatments for serious and untreatable ophthalmic conditions. The company's primary focus is on its lead drug candidate, an orally delivered compound aimed at addressing Stargardt disease and age-related macular degeneration. This innovative treatment has the potential to help medical professionals manage symptoms of irreversible vision loss early in life, offering hope to patients affected by these debilitating eye diseases.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Oort is an identity threat detection and response platform that focuses on enhancing enterprise security. Given that over 60% of security breaches involve the misuse of valid identity credentials, Oort recognizes identity as a critical perimeter that cannot be solely defended by personnel. The platform empowers cybersecurity and IT professionals to effectively manage their identity and access management (IAM) programs, providing full visibility and control over their identity attack surface. Oort's SaaS solution is designed for rapid deployment, allowing organizations to quickly reduce identity vulnerabilities at scale. Additionally, it offers network solutions through a network of globally distributed data centers, ensuring robust security for the digital supply chain. Based in Boston, MA, Oort operates as a fully remote startup and is supported by prominent investors such as Bain Capital Ventures, 645 Ventures, and First Star Ventures.

Oort is an identity threat detection and response platform that focuses on enhancing enterprise security. Given that over 60% of security breaches involve the misuse of valid identity credentials, Oort recognizes identity as a critical perimeter that cannot be solely defended by personnel. The platform empowers cybersecurity and IT professionals to effectively manage their identity and access management (IAM) programs, providing full visibility and control over their identity attack surface. Oort's SaaS solution is designed for rapid deployment, allowing organizations to quickly reduce identity vulnerabilities at scale. Additionally, it offers network solutions through a network of globally distributed data centers, ensuring robust security for the digital supply chain. Based in Boston, MA, Oort operates as a fully remote startup and is supported by prominent investors such as Bain Capital Ventures, 645 Ventures, and First Star Ventures.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Grid.ai, Inc. is a technology company that provides a platform for training artificial intelligence (AI) models using cloud-based graphics processing units (GPUs) and tensor processing units (TPUs). Founded in 2019 and headquartered in New York, the company offers tools such as Grid Train, which facilitates AI research by simplifying model training and iteration, and Grid View, a web application for monitoring and managing infrastructure. Additionally, it provides Tensorboard for experiment analysis. Grid.ai aims to support machine learning engineers, data scientists, and AI researchers by enabling the development of advanced AI models and end-to-end machine learning systems, known as Lightning Apps, that are multi-cloud and fault-tolerant. The company gained significant funding in October 2020, which has bolstered its mission to enhance AI capabilities for users.

HYCU is a leading provider of multi-cloud and SaaS data protection services, specializing in data backup and recovery solutions for on-premises, cloud-native, and SaaS environments. The company's R-Cloud platform streamlines data protection, migration, disaster recovery, and ransomware protection, addressing the complexities and costs associated with traditional data management solutions. By offering a comprehensive and user-friendly approach, HYCU aims to simplify the data monitoring and protection process for multi-cloud data centers. With a strong commitment to customer satisfaction, reflected in an impressive Net Promoter Score, HYCU has established itself as a trusted partner for thousands of companies worldwide. The company is headquartered in Boston, Massachusetts, and has secured significant venture capital funding to support its growth and innovation in the data protection landscape.

Cofactr, founded in 2021 by Matthew Haber and Phillip Gulley in New York, specializes in supply chain automation and procurement optimization for critical industries such as aerospace, defense, medtech, and robotics. The company offers an automated electronics purchasing assistant that aids hardware teams in sourcing necessary components by connecting them with global suppliers. Cofactr's platform features powerful supply chain intelligence, intuitive forecasting, transparent search capabilities, automated quoting, and instant purchasing. By streamlining these processes, Cofactr enables clients to proactively address sourcing challenges and reduce supply issues, ensuring the timely delivery of essential hardware.

Fidel API is a financial infrastructure platform that empowers developers to create programmable experiences in real-time during payment card transactions. By integrating directly with major payment networks like Visa and Mastercard, the platform provides granular transaction data, including amount, location, date, and merchant details. This enables businesses to enhance customer engagement and marketing efforts through real-time, event-driven interactions. Fidel API's technology facilitates the development of advanced loyalty and rewards programs, as well as streamlining processes such as reimbursements and expense management. Founded in 2018 and headquartered in London, Fidel API serves a diverse clientele ranging from startups to large enterprises, including notable organizations like Google and British Airways. The company is supported by significant investors and has a global presence with offices in Lisbon and New York, along with remote employees.

FreeWill Co. is a New York-based company that develops and operates an online estate planning platform. The service offers users access to legal forms and information, simplifying the process of estate planning and facilitating charitable donations. By providing free and user-friendly tools, FreeWill enables donors and fundraisers to make tax-advantaged gifts more easily, streamlining the process of making bequests and donations. The company's mission centers on addressing estate planning needs while promoting philanthropic efforts, ultimately making it simpler for individuals to contribute to charitable organizations.

Hometap is a fintech company founded in 2018 and based in Boston, Massachusetts, that specializes in home equity investments. It offers homeowners a unique opportunity to access cash without incurring debt or selling their property. By providing immediate funds in exchange for a percentage of the home's future value, Hometap enables homeowners to utilize the money for various purposes, such as paying off debt or financing renovations. This approach allows homeowners to improve their financial situation without the burden of monthly payments or additional loans.

Bain Capital, established in 1984, is a global multi-asset alternative investment firm with over $100 billion in assets under management. Headquartered in Boston, Massachusetts, the firm operates through several business units: Private Equity, Public Equity, Credit, and Venture Capital. Bain Capital Private Equity invests in various sectors, including consumer, healthcare, industrials, and technology, across North America, Europe, and Asia. Bain Capital Ventures, the venture capital arm, focuses on seed to growth-stage investments in enterprise software, infrastructure software, and industries being transformed by data. Bain Capital Life Sciences, a dedicated life sciences investment platform, invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Bain Capital Double Impact, the firm's impact investing arm, builds great companies that deliver both competitive financial returns and meaningful, measurable social and environmental good.

Socure Inc. is a provider of digital identity verification solutions, focusing on real-time identity authentication through its Socure ID+ platform. This predictive analytics platform utilizes artificial intelligence and machine learning to authenticate identities by analyzing a multitude of online and offline data sources, including email, phone numbers, addresses, IP addresses, and social media profiles. Socure's offerings include Aida, an AI-driven bot for validating digital identities, Docv, an omnichannel document verification solution, and Sigma Synthetic Fraud, which tackles synthetic identity fraud. The company addresses the needs of various sectors, including software, consulting, and financial firms, through compliance initiatives such as customer identification programs, know your customer requirements, and anti-money laundering measures. Founded in 2012 and headquartered in New York, Socure has established partnerships with key industry players to enhance its service delivery.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

ConvenientMD LLC is an urgent care provider that offers a wide range of medical services for non-life-threatening injuries and illnesses. Established in 2011 and headquartered in Portsmouth, New Hampshire, the company caters to patients seeking treatment for conditions such as sprains, fractures, cuts, colds, bronchitis, and urinary tract infections. Additionally, ConvenientMD provides preventive care services, including physicals, immunizations, and on-site prescriptions, as well as X-ray and lab services. Patients can access care without appointments from 8 am to 8 pm, seven days a week, with the expectation of being treated within an hour. The organization emphasizes quality care and customer service, employing a fully equipped medical team at its locations across New Hampshire, Maine, and Massachusetts, with plans for further expansion in New England.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Hand In Hand Soap, founded in 2011 by Bill Glaab and Courtney Apple, is a personal care brand based in Wynnewood, Pennsylvania. The company is committed to social responsibility through its Give Back program, which ensures that for every product sold, a bar of soap and access to clean water is donated to a child in need. Over the past decade, Hand In Hand has donated over 13 million bars of soap and provided thousands with clean water access. The brand's product range includes bar soap, liquid hand soap, hand sanitizer, body wash, sugar scrubs, and lotions. Additionally, Hand In Hand emphasizes sustainability by producing only palm oil-free products and raising awareness about the environmental and human rights issues associated with palm oil production.

Harry's Inc., established in 2012 and headquartered in New York, specializes in manufacturing and selling men's grooming products. The company produces a range of shaving items including razors, creams, kits, and face care products. Harry's operates an online platform where consumers can purchase these products individually or via a subscription service for convenient access to their grooming essentials.

HYCU is a leading provider of multi-cloud and SaaS data protection services, specializing in data backup and recovery solutions for on-premises, cloud-native, and SaaS environments. The company's R-Cloud platform streamlines data protection, migration, disaster recovery, and ransomware protection, addressing the complexities and costs associated with traditional data management solutions. By offering a comprehensive and user-friendly approach, HYCU aims to simplify the data monitoring and protection process for multi-cloud data centers. With a strong commitment to customer satisfaction, reflected in an impressive Net Promoter Score, HYCU has established itself as a trusted partner for thousands of companies worldwide. The company is headquartered in Boston, Massachusetts, and has secured significant venture capital funding to support its growth and innovation in the data protection landscape.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Hi Marley, Inc. is an innovative company based in Boston, Massachusetts, that specializes in enhancing communication within the insurance industry. Founded in 2017, it offers a platform named Marley, which integrates intelligent messaging with a human touch to facilitate seamless interactions between insurance companies and their customers. The platform enables insurers to efficiently manage conversations related to claims, underwriting, and policyholder services, ensuring that customers receive timely updates and responses to their inquiries. By bridging communication gaps, Hi Marley aims to improve customer satisfaction and streamline operations for auto, home, and business insurance providers.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space. The company's technology has the potential to address the unmet need in several kidney diseases, by further improving the standard of care, enabling medical practitioners to treat patients in a better way. River 3 Renal was established in 2020 in New York, USA.

TeachTown Inc. specializes in developing educational solutions for children diagnosed with autism spectrum disorder, developmental disabilities, intellectual disabilities, and emotional and behavioral disorders. The company's flagship products include TeachTown Basics, a computer-assisted instructional program that combines engaging computer lessons with motivating off-computer activities, and TeachTown Social Skills, an online curriculum that utilizes character-based video modeling to enhance social skills in elementary and middle school children. Additionally, TeachTown provides professional development resources for educators, enabling them to effectively implement its programs in the classroom. With a focus on improving academic, social, and emotional skills, TeachTown serves schools, families, and clinicians, facilitating the educational growth of children with special needs. Founded in 2001 and based in Woburn, Massachusetts, the company has positioned itself as a key resource in the field of special education.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

OpenFin Inc. specializes in providing runtime technology solutions tailored for financial desktops, enabling web applications to function outside traditional browser environments. Founded in 2010 and based in New York, with an additional office in London, the company serves clients in the financial services sector, including banks in the United States and Europe. OpenFin's platform facilitates real-time application generation, desktop notifications, and seamless communication between applications while adhering to stringent security and compliance standards required by financial institutions. This approach allows users to avoid costly packaging and deployment cycles, promoting rapid and secure application deployment.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

Grid.ai, Inc. is a technology company that provides a platform for training artificial intelligence (AI) models using cloud-based graphics processing units (GPUs) and tensor processing units (TPUs). Founded in 2019 and headquartered in New York, the company offers tools such as Grid Train, which facilitates AI research by simplifying model training and iteration, and Grid View, a web application for monitoring and managing infrastructure. Additionally, it provides Tensorboard for experiment analysis. Grid.ai aims to support machine learning engineers, data scientists, and AI researchers by enabling the development of advanced AI models and end-to-end machine learning systems, known as Lightning Apps, that are multi-cloud and fault-tolerant. The company gained significant funding in October 2020, which has bolstered its mission to enhance AI capabilities for users.

Nebulous, Inc. is a Boston-based company founded in 2014 that specializes in developing blockchain hardware and software infrastructure for the decentralized internet. The company is known for its flagship product, Sia, a decentralized cloud storage platform that utilizes blockchain technology to create a marketplace for data storage. Additionally, Nebulous offers Skynet, a decentralized content delivery network (CDN) and file-sharing platform aimed at developers, along with SiaStream, which provides affordable storage solutions for media files to enable fast streaming. As a core contributor and maintainer of the open-source Skynet project, Nebulous plays a significant role in advancing the decentralized web ecosystem.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that focuses on discovering and developing antiviral therapies for severe viral infections. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by SARS-CoV-2. Additionally, Atea is developing several other product candidates, including AT-787, which is in phase 2 trials for hepatitis C, and AT-752 for dengue. Other candidates, such as AT-889 and AT-934, are also in phase 2 clinical trials targeting respiratory syncytial virus. Established in 2014, Atea Pharmaceuticals aims to improve treatment options for patients suffering from serious viral infections.

BetterCloud, Inc. specializes in cloud office solutions, focusing on SaaS management for organizations globally. Founded in 2012 and headquartered in New York, with an additional location in Atlanta, BetterCloud provides a centralized platform that offers insights into employee SaaS adoption, streamlining IT decision-making and license management across various applications. The company's services include user lifecycle management, data discovery, security automation, and IT automation. Its automation engine, Workflows, orchestrates complex processes, ensuring accuracy and compliance. BetterCloud also features platform APIs for securing SaaS ecosystems and tools for content scanning across major platforms such as Google Drive, Microsoft SharePoint, and Slack. Serving a diverse range of sectors, including healthcare, education, and technology, BetterCloud empowers IT professionals to enhance productivity and security while managing an increasingly complex landscape of SaaS applications.

Broadstep Behavioral Health provides a continuum of physical, emotional, and mental support for children and adults with intellectual and development disabilities (I/DD), mental illness, and co-occurring disorders. Broadstep has grown to now serve more than 1,300 individuals in 86 facilities across Wisconsin, North Carolina, New Jersey, Illinois and South Carolina. With outcomes rooted in discovering and championing personal definitions of progress, our individuals, families, caregivers, and neighbors are building more and more communities people can call home.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Hi Marley, Inc. is an innovative company based in Boston, Massachusetts, that specializes in enhancing communication within the insurance industry. Founded in 2017, it offers a platform named Marley, which integrates intelligent messaging with a human touch to facilitate seamless interactions between insurance companies and their customers. The platform enables insurers to efficiently manage conversations related to claims, underwriting, and policyholder services, ensuring that customers receive timely updates and responses to their inquiries. By bridging communication gaps, Hi Marley aims to improve customer satisfaction and streamline operations for auto, home, and business insurance providers.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Justworks, Inc. is a New York-based company founded in 2012 that offers a comprehensive software platform designed to simplify payroll, benefits, human resources, and compliance for small and medium-sized businesses. By serving as a professional employer organization, Justworks enables businesses to bundle essential employment-related functions, allowing them to efficiently manage payroll, employee information, and compliance requirements. The platform also provides access to affordable health insurance and benefits, along with self-service capabilities for businesses to navigate workforce management confidently. Justworks enhances operational efficiency and cost savings through its cloud-based solutions, offering 24/7 support and expertise tailored for modern business needs.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's primary product candidate, ganaxolone, is an allosteric modulator of GABAA receptors, designed for both intravenous and oral administration for various patient populations. It aims to address multiple indications, including status epilepticus, cyclin dependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals collaborates with NovaMedica and has license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals to advance its research and therapeutic offerings. Founded in 2003, the company is headquartered in Radnor, Pennsylvania.

Grid.ai, Inc. is a technology company that provides a platform for training artificial intelligence (AI) models using cloud-based graphics processing units (GPUs) and tensor processing units (TPUs). Founded in 2019 and headquartered in New York, the company offers tools such as Grid Train, which facilitates AI research by simplifying model training and iteration, and Grid View, a web application for monitoring and managing infrastructure. Additionally, it provides Tensorboard for experiment analysis. Grid.ai aims to support machine learning engineers, data scientists, and AI researchers by enabling the development of advanced AI models and end-to-end machine learning systems, known as Lightning Apps, that are multi-cloud and fault-tolerant. The company gained significant funding in October 2020, which has bolstered its mission to enhance AI capabilities for users.

ACV provides a pricing application (app) for franchise dealers. It offers ACV, a mobile auction platform that enables wholesale dealers to sell trade-ins by creating app-based auctions.

Ribbon Home, Inc. is an online real estate platform founded in 2017 and based in New York, New York. The company facilitates the buying and selling of properties, offering services that enable homeowners to purchase new homes before selling their existing ones. By collaborating with local realtors, Ribbon Home provides clients with the opportunity to secure their desired homes while allowing them the time and flexibility to sell their current properties at favorable prices. The company aims to simplify the home buying process, making it more accessible and less stressful for families. Additionally, Ribbon Home offers financing and leasing services to support buyers in acquiring their homes.

The Yes is an artificial intelligence-based shopping platform founded in 2018 and headquartered in Burlingame, California, with additional operations in New York City. The company aims to transform the e-commerce landscape by leveraging AI technology to enhance the online shopping experience. By focusing on innovative solutions, The Yes seeks to attract critical thinkers who can contribute to reimagining the rules of online retail. The platform is dedicated to creating a dynamic and engaging shopping environment for users.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Idelic is a driver management platform founded in 2016 and based in Pittsburgh, Pennsylvania. It focuses on the transportation industry by consolidating fleet data systems and automating compliance processes to enhance driver safety. The platform integrates data from various technology sources into a unified system, allowing clients to gain predictive insights and effectively manage their safety operations. By leveraging data organization and artificial intelligence, Idelic aims to prevent crashes, reduce driver turnover, and lower insurance costs. The company's innovative approach helps identify at-risk drivers before incidents occur, contributing to a safer and more efficient fleet management experience.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Nebulous, Inc. is a Boston-based company founded in 2014 that specializes in developing blockchain hardware and software infrastructure for the decentralized internet. The company is known for its flagship product, Sia, a decentralized cloud storage platform that utilizes blockchain technology to create a marketplace for data storage. Additionally, Nebulous offers Skynet, a decentralized content delivery network (CDN) and file-sharing platform aimed at developers, along with SiaStream, which provides affordable storage solutions for media files to enable fast streaming. As a core contributor and maintainer of the open-source Skynet project, Nebulous plays a significant role in advancing the decentralized web ecosystem.

TruVideo, Inc. is a company that develops a video and text communication platform tailored for auto repair shops. Founded in 2015 and headquartered in Wellesley, Massachusetts, TruVideo provides an application that enables technicians to record videos showcasing the condition of vehicles and the necessary repairs. This platform allows repair shops to enhance customer engagement by sending personalized video narratives to clients, fostering transparency and trust. Additionally, the service includes mobile payment options, enabling customers to approve repairs and complete payments seamlessly. By offering these tools, TruVideo aims to improve the communication between service providers and their customers, ultimately enhancing the overall experience in the automotive service sector.

OpenFin Inc. specializes in providing runtime technology solutions tailored for financial desktops, enabling web applications to function outside traditional browser environments. Founded in 2010 and based in New York, with an additional office in London, the company serves clients in the financial services sector, including banks in the United States and Europe. OpenFin's platform facilitates real-time application generation, desktop notifications, and seamless communication between applications while adhering to stringent security and compliance standards required by financial institutions. This approach allows users to avoid costly packaging and deployment cycles, promoting rapid and secure application deployment.

Robot Ventures is a venture capital firm established in 2019 and based in New York, specializing in early-stage investments in the fintech and blockchain sectors. The firm focuses on (pre-)seed funding for innovative companies that are led by founders with ambitious visions and unconventional perspectives. By targeting exceptional startups within the cryptocurrency and financial technology domains, Robot Ventures aims to support and nurture transformative ideas that challenge traditional business models.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Rent the Runway, Inc. is an e-commerce platform that allows women to rent designer apparel and accessories, offering a transformative approach to fashion consumption. Founded in 2008 and based in New York, the company provides a range of options including party dresses, gowns, jumpsuits, outerwear, and accessories such as jewelry and handbags. Rent the Runway operates both an online platform and physical stores in locations like New York City, San Francisco, Santa Monica, and Washington, D.C. Through its subscription model, users can access an extensive collection of clothing for various occasions, while also having the option to rent items a-la-carte or purchase them outright. The company emphasizes sustainability and empowerment, catering to modern women's needs in a rapidly evolving fashion landscape.

ACV provides a pricing application (app) for franchise dealers. It offers ACV, a mobile auction platform that enables wholesale dealers to sell trade-ins by creating app-based auctions.

Idelic is a driver management platform founded in 2016 and based in Pittsburgh, Pennsylvania. It focuses on the transportation industry by consolidating fleet data systems and automating compliance processes to enhance driver safety. The platform integrates data from various technology sources into a unified system, allowing clients to gain predictive insights and effectively manage their safety operations. By leveraging data organization and artificial intelligence, Idelic aims to prevent crashes, reduce driver turnover, and lower insurance costs. The company's innovative approach helps identify at-risk drivers before incidents occur, contributing to a safer and more efficient fleet management experience.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Ribbon Home, Inc. is an online real estate platform founded in 2017 and based in New York, New York. The company facilitates the buying and selling of properties, offering services that enable homeowners to purchase new homes before selling their existing ones. By collaborating with local realtors, Ribbon Home provides clients with the opportunity to secure their desired homes while allowing them the time and flexibility to sell their current properties at favorable prices. The company aims to simplify the home buying process, making it more accessible and less stressful for families. Additionally, Ribbon Home offers financing and leasing services to support buyers in acquiring their homes.

Rocket Software, Inc. is a provider of enterprise software solutions that focuses on IT modernization and automation services. Established in 1990 and headquartered in Waltham, Massachusetts, the company offers a wide range of products including application lifecycle management, business intelligence, data migration, enterprise performance management, and mainframe modernization. It serves numerous industries, such as automotive, healthcare, finance, and technology, providing tools and services that help businesses optimize their infrastructure, data, and applications. Additionally, Rocket Software offers training, technical support, and professional services to help clients navigate complex IT challenges and enhance their operational capabilities. With a global presence across North America, Europe, and the Asia-Pacific region, Rocket Software is committed to delivering innovative solutions tailored to meet the evolving needs of its diverse customer base.

Unioncrate, Inc. develops artificial intelligence-driven supply chain management software tailored for consumer goods companies. Founded in 2016 and headquartered in New York City, with additional offices in Barcelona and Buenos Aires, Unioncrate offers products like Stargate, which manages sales and purchase orders, suppliers, inventory, reporting, trade spend, and EDI. Another key product, Almanac, focuses on consumption-driven predictions. The company aims to enhance supply chain efficiency by providing accurate demand forecasts and collaborative visibility while automating operational tasks. By leveraging AI, Unioncrate addresses the operational challenges faced by businesses in a rapidly evolving market, moving away from outdated supply chain systems and helping clients recover valuable time and resources.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

ObserveIT LTD. specializes in insider threat management software solutions aimed at helping organizations identify and mitigate insider threats. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company provides a comprehensive platform that includes insider threat detection, investigation, and prevention tools. Its services encompass data loss detection, user activity monitoring, incident response, and compliance solutions. By offering full playback of security incidents, ObserveIT enables security teams to reduce investigation times significantly and enhance response efficiency. The company's solutions are utilized by over 1,600 global customers across various industries, including financial services, technology, and manufacturing, to secure remote workers and protect against data loss. ObserveIT operates as a subsidiary of Proofpoint, Inc.

Alice, Inc. is a financial services company that specializes in artificial intelligence-enabled payroll management software. Founded in 2015 and based in Brooklyn, New York, the company focuses on automating pre-tax spending for employees. Its software integrates with existing payroll systems to identify eligible pre-tax expenses, such as commuting costs and medical care. The platform communicates with employees via text to confirm transactions and updates payroll accordingly to reflect tax refunds. In addition to simplifying the benefits process for employees, Alice supports human resource professionals during onboarding, enhancing the overall management of employee benefits while helping employers reduce payroll tax liabilities.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Penn Foster College, Penn Foster Career School, and Penn Foster High School are part of Penn Foster, Inc., a global leader in online education. For more than 118 years, Penn Foster has been providing accredited career-focused degree and vocational programs in the fields of allied health, business, technology, education, and select trades. Nationally and regionally accredited Penn Foster High School (www.PennFosterHighSchool.com) and Penn Foster Career School (www.pennfoster.edu) are headquartered in Scranton, PA, with regional offices in Montreal, Canada. Penn Foster College is headquartered in Scottsdale, Arizona.

ObserveIT LTD. specializes in insider threat management software solutions aimed at helping organizations identify and mitigate insider threats. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company provides a comprehensive platform that includes insider threat detection, investigation, and prevention tools. Its services encompass data loss detection, user activity monitoring, incident response, and compliance solutions. By offering full playback of security incidents, ObserveIT enables security teams to reduce investigation times significantly and enhance response efficiency. The company's solutions are utilized by over 1,600 global customers across various industries, including financial services, technology, and manufacturing, to secure remote workers and protect against data loss. ObserveIT operates as a subsidiary of Proofpoint, Inc.

BetterCloud, Inc. specializes in cloud office solutions, focusing on SaaS management for organizations globally. Founded in 2012 and headquartered in New York, with an additional location in Atlanta, BetterCloud provides a centralized platform that offers insights into employee SaaS adoption, streamlining IT decision-making and license management across various applications. The company's services include user lifecycle management, data discovery, security automation, and IT automation. Its automation engine, Workflows, orchestrates complex processes, ensuring accuracy and compliance. BetterCloud also features platform APIs for securing SaaS ecosystems and tools for content scanning across major platforms such as Google Drive, Microsoft SharePoint, and Slack. Serving a diverse range of sectors, including healthcare, education, and technology, BetterCloud empowers IT professionals to enhance productivity and security while managing an increasingly complex landscape of SaaS applications.

World Wide Packaging LLC is a designer and manufacturer of packaging products tailored for the cosmetic, skincare, and personal care markets. Established in 1980 and headquartered in Florham Park, New Jersey, the company operates an additional facility in Woodland Hills, California. Its extensive product offerings include a variety of packaging solutions such as blush and foundation sticks, cosmetic bottles, metal and plastic lipstick cases, compacts, jars, and tubes for lip gloss, eyeliner, and mascara. Furthermore, World Wide Packaging provides contract manufacturing services that encompass market research, product development, formulation, filling, and secondary packaging solutions. The company is known for its custom-engineered solutions and offers a range of products from basic plastic containers to sophisticated metal packaging, ensuring high quality and competitive pricing for its clients.

Justworks, Inc. is a New York-based company founded in 2012 that offers a comprehensive software platform designed to simplify payroll, benefits, human resources, and compliance for small and medium-sized businesses. By serving as a professional employer organization, Justworks enables businesses to bundle essential employment-related functions, allowing them to efficiently manage payroll, employee information, and compliance requirements. The platform also provides access to affordable health insurance and benefits, along with self-service capabilities for businesses to navigate workforce management confidently. Justworks enhances operational efficiency and cost savings through its cloud-based solutions, offering 24/7 support and expertise tailored for modern business needs.

Bench Accounting Inc. is a fintech company based in Vancouver, Canada, that specializes in providing online bookkeeping services for small businesses. Founded in 2012, the company combines intuitive software with a dedicated team of professional bookkeepers to automate accounting tasks, allowing clients to manage their finances more efficiently. Bench offers a range of services, including monthly financial statements, year-end financials, and year-round tax support, ensuring that business owners have access to comprehensive financial reporting and expert assistance. With a focus on affordability and convenience, Bench aims to streamline the bookkeeping process, empowering clients to concentrate on growing their businesses. The company has raised significant funding to support its operations and currently employs a workforce dedicated to serving thousands of clients across Canada.

Basis, established in 2017 and headquartered in Hoboken, New Jersey, specializes in developing an algorithmic cryptocurrency protocol. This protocol is designed to stabilize purchasing power by automatically adjusting the supply of its cryptocurrency, similar to how central banks manage fiscal debt.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

mParticle, Inc. is a New York-based company that develops a customer data platform designed for multi-channel consumer brands. Founded in 2012, mParticle enables businesses to effectively manage and analyze customer data in real time, providing tools for marketers, developers, and data scientists to integrate and orchestrate their marketing efforts. The platform collects user data from various sources, unifying it into a single view to deliver personalized, omnichannel customer experiences. This capability allows companies to gain actionable insights, optimize customer journeys, and enhance engagement through advanced analytics and audience segmentation. mParticle serves a diverse range of industries, including retail, financial services, media, dining, travel, gaming, and marketing, among others, helping brands accelerate their growth strategies while ensuring compliance with regulations such as GDPR. The company also has additional offices in San Francisco, Bellevue, London, and Delray Beach.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's primary product candidate, ganaxolone, is an allosteric modulator of GABAA receptors, designed for both intravenous and oral administration for various patient populations. It aims to address multiple indications, including status epilepticus, cyclin dependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals collaborates with NovaMedica and has license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals to advance its research and therapeutic offerings. Founded in 2003, the company is headquartered in Radnor, Pennsylvania.

Replimune Group, Inc., established in 2015 and based in Woburn, Massachusetts, is a biotechnology company specializing in the development of oncolytic immune-gene therapies for cancer treatment. The company's proprietary Immulytic platform enables the design of product candidates that directly attack cancer cells and stimulate the immune system. Replimune's lead candidate, RP1, is a modified herpes simplex virus currently in Phase I/II trials for various solid tumors and Phase II trials for cutaneous squamous cell carcinoma. Additionally, RP2 and RP3 are in early-stage clinical trials, targeting immune checkpoint inhibition and T-cell stimulation, respectively. Replimune aims to rapidly advance these therapies through clinical trials and explore combinations with other immuno-oncology products.

EverTrue, Inc. is a software company based in Boston, Massachusetts, that provides a comprehensive platform designed to enhance fundraising efforts at educational institutions. Founded in 2010, the company connects institutional data with insights from various social and demographic sources, including LinkedIn, Facebook, and the U.S. Census. This integration allows advancement offices to better understand and segment their constituents, identify potential donors, and effectively plan events and trips. EverTrue's suite of products includes solutions for alumni community engagement, online giving, relationship management, and volunteer management, serving over 300 institutions. The platform equips fundraising teams with the necessary tools to engage alumni, raise financial support, and track their progress through improved data accessibility and user-friendly functionalities.

GraniteShares is an independent ETF company based in New York City that aims to provide innovative and cost-effective investment solutions. The company specializes in launching disruptive exchange-traded funds (ETFs) focused on commodities and alternative investments. By leveraging new ideas and structures, GraniteShares seeks to enhance the investment experience while significantly reducing costs for investors. Its platform offers a range of ETFs designed to provide exposure to various asset classes, enabling investors to avoid high fees associated with actively managed funds and inefficient investment strategies.

Flow Commerce, Inc. is a technology company that specializes in cross-border e-commerce solutions. Founded in 2015 and headquartered in Hoboken, New Jersey, with an additional office in Dublin, Ireland, Flow provides a comprehensive platform that simplifies international selling for e-commerce businesses. Its services enable merchants to configure their cross-border supply-chain requirements efficiently, making it easier to capture global demand for their products. The platform addresses various aspects of international transactions, including multi-currency pricing, shipping logistics, payment processing, and tax calculations, while utilizing artificial intelligence to streamline operations. Flow's solution is versatile, catering to businesses of all sizes and can be implemented as a complete system or as modular components, ensuring a seamless experience for both merchants and consumers in the global marketplace.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

OpenFin Inc. specializes in providing runtime technology solutions tailored for financial desktops, enabling web applications to function outside traditional browser environments. Founded in 2010 and based in New York, with an additional office in London, the company serves clients in the financial services sector, including banks in the United States and Europe. OpenFin's platform facilitates real-time application generation, desktop notifications, and seamless communication between applications while adhering to stringent security and compliance standards required by financial institutions. This approach allows users to avoid costly packaging and deployment cycles, promoting rapid and secure application deployment.